BioSenic S.A. (BIOS.BR)
EUR 0.01
(-5.71%)
EUR 0.01
(-5.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.04 Million EUR | -203.71% |
| 2022 | -2.31 Million EUR | 80.73% |
| 2021 | -12.02 Million EUR | 19.92% |
| 2020 | -15.01 Million EUR | -34.39% |
| 2019 | -11.17 Million EUR | 2.55% |
| 2018 | -11.46 Million EUR | 6.73% |
| 2017 | -12.29 Million EUR | 3.95% |
| 2016 | -12.79 Million EUR | -4.7% |
| 2015 | -12.22 Million EUR | -117.28% |
| 2014 | -5.62 Million EUR | -39.15% |
| 2013 | -4.04 Million EUR | -10.4% |
| 2012 | -3.66 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -233.5 Thousand EUR | 0.0% |
| 2024 Q1 | -233.5 Thousand EUR | 85.13% |
| 2023 FY | -7.58 Million EUR | -227.09% |
| 2023 Q1 | -1.95 Million EUR | -112.01% |
| 2023 Q2 | -4.26 Million EUR | -118.71% |
| 2023 Q3 | -1.56 Million EUR | 63.22% |
| 2023 Q4 | -1.57 Million EUR | -0.06% |
| 2022 Q4 | -920 Thousand EUR | 0.0% |
| 2022 FY | -2.31 Million EUR | 80.73% |
| 2022 Q3 | -920 Thousand EUR | 78.88% |
| 2022 Q2 | -4.35 Million EUR | 0.0% |
| 2021 Q4 | -7.27 Million EUR | 0.0% |
| 2021 FY | -12.02 Million EUR | 19.92% |
| 2021 Q2 | -6.49 Million EUR | 0.0% |
| 2020 Q4 | -7.54 Million EUR | 0.0% |
| 2020 FY | -15.01 Million EUR | -34.39% |
| 2020 Q2 | -10.13 Million EUR | 0.0% |
| 2019 FY | -11.17 Million EUR | 2.55% |
| 2019 Q2 | -7.11 Million EUR | 0.0% |
| 2019 Q4 | -7.38 Million EUR | 0.0% |
| 2018 Q4 | -7.58 Million EUR | 0.0% |
| 2018 FY | -11.46 Million EUR | 6.73% |
| 2017 FY | -12.29 Million EUR | 3.95% |
| 2016 FY | -12.79 Million EUR | -4.7% |
| 2015 FY | -12.22 Million EUR | -117.28% |
| 2014 Q3 | -1.08 Million EUR | 0.0% |
| 2014 FY | -5.62 Million EUR | -39.15% |
| 2014 Q4 | -1.88 Million EUR | -74.35% |
| 2013 Q4 | -1.31 Million EUR | 0.0% |
| 2013 FY | -4.04 Million EUR | -10.4% |
| 2012 FY | -3.66 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -106.331% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 94.473% |
| Adocia SA | -17.62 Million EUR | 60.05% |
| Aelis Farma SA | -6.46 Million EUR | -8.961% |
| Biophytis S.A. | -14.33 Million EUR | 50.883% |
| Advicenne S.A. | -6.45 Million EUR | -9.029% |
| genOway Société anonyme | 2.06 Million EUR | 440.871% |
| IntegraGen SA | -183.77 Thousand EUR | -3730.876% |
| Medesis Pharma S.A. | -4.22 Million EUR | -66.456% |
| Neovacs S.A. | -6.9 Million EUR | -1.917% |
| NFL Biosciences SA | -4.43 Million EUR | -58.901% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -804.609% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -124.4% |
| Sensorion SA | -22.31 Million EUR | 68.446% |
| Theranexus Société Anonyme | -7.64 Million EUR | 7.898% |
| TME Pharma N.V. | -5.62 Million EUR | -25.178% |
| Valbiotis SA | -7.16 Million EUR | 1.676% |
| TheraVet SA | -2.17 Million EUR | -223.662% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 65.3% |
| argenx SE | -417.15 Million EUR | 98.312% |
| Celyad Oncology SA | -8.45 Million EUR | 16.755% |
| DBV Technologies S.A. | -85.24 Million EUR | 91.742% |
| Galapagos NV | -88.26 Million EUR | 92.024% |
| Genfit S.A. | -26.58 Million EUR | 73.514% |
| GeNeuro SA | -14.35 Million EUR | 50.966% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 55.981% |
| Innate Pharma S.A. | -12.66 Million EUR | 44.431% |
| Inventiva S.A. | -102.7 Million EUR | 93.146% |
| MaaT Pharma SA | -19.94 Million EUR | 64.699% |
| MedinCell S.A. | -20.97 Million EUR | 66.439% |
| Nanobiotix S.A. | -26.77 Million EUR | 73.711% |
| Onward Medical N.V. | -35.46 Million EUR | 80.148% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -54.753% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 69.373% |
| Oxurion NV | -12.11 Million EUR | 41.866% |
| Pharming Group N.V. | -4.87 Million EUR | -44.276% |
| Poxel S.A. | -28.76 Million EUR | 75.525% |
| GenSight Biologics S.A. | -29.69 Million EUR | 76.293% |
| Transgene SA | -30.01 Million EUR | 76.543% |
| Financière de Tubize SA | -2.14 Million EUR | -228.362% |
| UCB SA | 604 Million EUR | 101.166% |
| Valneva SE | -82.08 Million EUR | 91.424% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 75.587% |